These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 17453000)

  • 1. Alteration of the serum levels of the epidermal growth factor receptor and its ligands in patients with non-small cell lung cancer and head and neck carcinoma.
    Lemos-González Y; Rodríguez-Berrocal FJ; Cordero OJ; Gómez C; Páez de la Cadena M
    Br J Cancer; 2007 May; 96(10):1569-78. PubMed ID: 17453000
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of the prognostic value of soluble epidermal growth factor receptor plasma concentration in advanced non-small-cell lung cancer patients.
    Jantus-Lewintre E; Sirera R; Cabrera A; Blasco A; Caballero C; Iranzo V; Rosell R; Camps C
    Clin Lung Cancer; 2011 Sep; 12(5):320-7. PubMed ID: 21729651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increases of amphiregulin and transforming growth factor-alpha in serum as predictors of poor response to gefitinib among patients with advanced non-small cell lung cancers.
    Ishikawa N; Daigo Y; Takano A; Taniwaki M; Kato T; Hayama S; Murakami H; Takeshima Y; Inai K; Nishimura H; Tsuchiya E; Kohno N; Nakamura Y
    Cancer Res; 2005 Oct; 65(20):9176-84. PubMed ID: 16230376
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung.
    Rusch V; Baselga J; Cordon-Cardo C; Orazem J; Zaman M; Hoda S; McIntosh J; Kurie J; Dmitrovsky E
    Cancer Res; 1993 May; 53(10 Suppl):2379-85. PubMed ID: 7683573
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preliminary Evidence on the Diagnostic and Molecular Role of Circulating Soluble EGFR in Non-Small Cell Lung Cancer.
    Lococo F; Paci M; Rapicetta C; Rossi T; Sancisi V; Braglia L; Cavuto S; Bisagni A; Bongarzone I; Noonan DM; Albini A; Maramotti S
    Int J Mol Sci; 2015 Aug; 16(8):19612-30. PubMed ID: 26295387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum sErbB1 and epidermal growth factor levels as tumor biomarkers in women with stage III or IV epithelial ovarian cancer.
    Baron AT; Lafky JM; Boardman CH; Balasubramaniam S; Suman VJ; Podratz KC; Maihle NJ
    Cancer Epidemiol Biomarkers Prev; 1999 Feb; 8(2):129-37. PubMed ID: 10067810
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma transforming growth factor alpha and amphiregulin protein levels in NCIC Clinical Trials Group BR.21.
    Addison CL; Ding K; Zhao H; Le Maître A; Goss GD; Seymour L; Tsao MS; Shepherd FA; Bradbury PA
    J Clin Oncol; 2010 Dec; 28(36):5247-56. PubMed ID: 21079146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression.
    Rusch V; Klimstra D; Venkatraman E; Pisters PW; Langenfeld J; Dmitrovsky E
    Clin Cancer Res; 1997 Apr; 3(4):515-22. PubMed ID: 9815714
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prognostic value of serum epidermal growth factor receptor level in patients with non-small cell lung cancer.
    Ciledağ A; Kaya A; Yetkin O; Poyraz B; Savaş I; Numanoğlu N; Savaş H
    Tuberk Toraks; 2008; 56(4):390-5. PubMed ID: 19123074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Soluble epidermal growth factor receptor (sEGFR/sErbB1) as a potential risk, screening, and diagnostic serum biomarker of epithelial ovarian cancer.
    Baron AT; Cora EM; Lafky JM; Boardman CH; Buenafe MC; Rademaker A; Liu D; Fishman DA; Podratz KC; Maihle NJ
    Cancer Epidemiol Biomarkers Prev; 2003 Feb; 12(2):103-13. PubMed ID: 12582019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Soluble epidermal growth factor receptor isoforms in non-small cell lung cancer tissue and in blood.
    Maramotti S; Paci M; Miccichè F; Ciarrocchi A; Cavazza A; De Bortoli M; Vaghi E; Formisano D; Canovi L; Sgarbi G; Bongarzone I
    Lung Cancer; 2012 Jun; 76(3):332-8. PubMed ID: 22177532
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer.
    Baron AT; Boardman CH; Lafky JM; Rademaker A; Liu D; Fishman DA; Podratz KC; Maihle NJ
    Cancer Epidemiol Biomarkers Prev; 2005 Feb; 14(2):306-18. PubMed ID: 15734951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pretreatment serum levels of cytokines and cytokine receptors in patients with non-small cell lung cancer, and correlations with clinicopathological features and prognosis. M-CSF - an independent prognostic factor.
    Kaminska J; Kowalska M; Kotowicz B; Fuksiewicz M; Glogowski M; Wojcik E; Chechlinska M; Steffen J
    Oncology; 2006; 70(2):115-25. PubMed ID: 16645324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical efficacy of erlotinib in patients previously treated for advanced non-small cell lung cancer.
    Zhou S; Ren S; Yan L; Zhang L; Tang L; Zhang J; Zhou C
    Respirology; 2009 Jul; 14(5):709-15. PubMed ID: 19659649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical significance of epidermal growth factor receptor mutations and insulin-like growth factor 1 and its binding protein 3 in advanced non-squamous non-small cell lung cancer.
    Masago K; Fujita S; Togashi Y; Kim YH; Hatachi Y; Fukuhara A; Nagai H; Irisa K; Sakamori Y; Mio T; Mishima M
    Oncol Rep; 2011 Oct; 26(4):795-803. PubMed ID: 21805046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A subclass of HER1 ligands are prognostic markers for survival in bladder cancer patients.
    Thøgersen VB; Sørensen BS; Poulsen SS; Orntoft TF; Wolf H; Nexo E
    Cancer Res; 2001 Aug; 61(16):6227-33. PubMed ID: 11507076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utility of plasma tumour necrosis factor-alpha and transforming growth factor-beta1 as predictors of survival and treatment outcome in advanced non-small cell lung carcinoma.
    Kumar S; Guleria R; Mohan A; Singh V; Ali A; Bharti AC; Das BC
    Biomarkers; 2010 Aug; 15(5):446-53. PubMed ID: 20486867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I-IIIA non-small-cell lung cancer: amphiregulin and microvessel count are independent prognostic indicators of survival.
    Fontanini G; De Laurentiis M; Vignati S; Chinè S; Lucchi M; Silvestri V; Mussi A; De Placido S; Tortora G; Bianco AR; Gullick W; Angeletti CA; Bevilacqua G; Ciardiello F
    Clin Cancer Res; 1998 Jan; 4(1):241-9. PubMed ID: 9516978
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p53 protein, EGF receptor, and anti-p53 antibodies in serum from patients with occupationally derived lung cancer.
    Schneider J; Presek P; Braun A; Bauer P; Konietzko N; Wiesner B; Woitowitz HJ
    Br J Cancer; 1999 Aug; 80(12):1987-94. PubMed ID: 10471051
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced non-small-cell lung cancer.
    Neninger Vinageras E; de la Torre A; Osorio Rodríguez M; Catalá Ferrer M; Bravo I; Mendoza del Pino M; Abreu Abreu D; Acosta Brooks S; Rives R; del Castillo Carrillo C; González Dueñas M; Viada C; García Verdecia B; Crombet Ramos T; González Marinello G; Lage Dávila A
    J Clin Oncol; 2008 Mar; 26(9):1452-8. PubMed ID: 18349395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.